GlobeImmune lands $41M venture round

With its lead drug in Phase II for pancreatic cancer and a hepatitis C drug slated to forge into a mid-stage study later this year, GlobeImmune has rounded up $41.2 million in its third round of venture financing. That money came from a long list of new and existing investors, which includes Celgene, Boston Life Science Venture, Morgenthaler Ventures and Biogen Idec. Wexford Capital led the round. GlobeImmune has raised a total of $88 million in financing to date.

In an interview with FierceBiotech, GlobeImmune CEO Timothy C. Rodell M.D., noted that the financing would get the company to Phase II data on its two lead programs. By that stage, the company would have a chance to fully evaluate how it would like to push ahead, including potential partnerships or possibly an IPO. GlobeImmune is advancing therapies based on a proprietary platform that offers a new approach to triggering a potent T-cell response to infectious diseases and cancer. We'll have more on the company's plans--and platform--in our Friday profile on emerging biotech companies.

- check out this release on the round

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.